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Abstract
Introduction: Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90%
5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional
adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients.
The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk
groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated
in a single center with breast-conserving surgery and long-term follow-up.
Methods: Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local
excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained,
197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a
combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal,
23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm
2 tissue
microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was
assigned a Mammostrat® risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and
overall survival (OS) were analyzed by marker positivity and risk score.
Results: Increased Mammostrat® scores were significantly associated with reduced DRFS, RFS and OS in estrogen
receptor (ER)-positive breast cancer (P < 0.00001). In multivariate analyses the risk score was independent of
conventional risk factors for DRFS, RFS and OS (P < 0.05). In node-negative, tamoxifen-treated patients, 10-year
recurrence rates were 7.6 ± 1.5% in the low-risk group versus 20.0 ± 4.4% in the high-risk group. Further,
exploratory analyses revealed associations with outcome in both ER-negative and untreated patients.
Conclusions: This is the fifth independent study providing evidence that Mammostrat® can act as an independent
prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a
possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context
of previous results, these data provide further support for this antibody panel as an aid to patient management in
early-stage breast cancer.
* Correspondence: john.bartlett@ed.ac.uk
1Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh
University, Carrington Crescent, Edinburgh EH4 2XU, UK
Bartlett et al. Breast Cancer Research 2010, 12:R47
http://breast-cancer-research.com/content/12/4/R47
© 2010 Bartlett et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
E n d o c r i n et h e r a p yi sah i g h l ye f f e c t i v ea d j u v a n tt h e r a p y
for estrogen receptor (ER)-positive early breast cancer
[1-3]. However, critical reviews of the early tamoxifen
trials, with extensive follow-up [1], demonstrate that
many patients derive little or no lasting benefit from
adjuvant tamoxifen therapy [1]. Evidence from over
40,000 women randomized between no adjuvant therapy
and 5 years of tamoxifen demonstrated that > 50% of
women with node-negative breast cancer receiving no
adjuvant treatment were disease free 15 years later.
Adjuvant tamoxifen prevented relapse in < 14% of
patients whilst > 34% experienced disease relapse
(almost half whilst receiving tamoxifen therapy [1]).
The recent development of third-generation aromatase
inhibitors has shown statistically significant and clini-
cally useful improvements in outcome, versus tamoxifen,
in ER-positive breast cancers. However, the proportion
of patients deriving added benefit is small, particularly
in the first 2 to 3 years of treatment [4]. A recent over-
view of two trials comparing aromatase inhibitors
against tamoxifen (Arimidex, Tamoxifen, Alone or in
Combination Trial and Breast International Group-1-98)
suggests that during the first 2 years of treatment with
aromatase inhibitors only one recurrence was prevented
for every 100 to 150 patients treated [5,6].
It is now widely acknowledged that ER-expressing breast
cancer is biologically heterogeneous and that this com-
plexity accounts for part of the variation in clinical out-
come [7]. The challenge is to exploit this knowledge to
optimize adjuvant therapy for early ER-positive breast can-
cers. To date, clinicians have relied upon clinical and
pathologic factors to predict outcome and select adjuvant
therapy. Combinations of risk factors such as the Notting-
ham Prognostic Index [8] and Adjuvant Online! [9] are
useful for risk-stratifying patients, especially when patients
fall into either high-risk or low-risk strata. Documented
variation in outcome for patients with similar risk profiles,
however, makes it clear that there is considerable clinical
diversity not accounted for by these classifiers.
More recently, the advent of genome-wide cDNA
microarrays revealed that tumor specimens could be
classified according to gene expression profiles [10-12].
This information has begun to be translated into clinical
assays to predict outcome and response to therapy. Two
such assays relying upon measurement of gene expres-
sion in tumor RNA - OncotypeDx and Mammaprint
[13,14] - are currently being evaluated in prospective
clinical trials. These molecular assays in large part mea-
sure the same biology assessed by conventional patholo-
gic tools; for example, proliferation, grade (not
independent from proliferation), and hormone receptor
status. These assays are relatively high cost, technically
demanding (to the extent they are performed only in
single centers at present), and therefore potentially lim-
ited in their ultimate utility.
An alternative approach has been utilized to develop
the immunohistochemical (IHC) assay Mammostrat®,
with potential for implementation in routine pathology
assessment of breast cancers. Combining the novel
information that has emerged from gene expression pro-
filing experiments with conventional IHC technology led
to the design of a five-biomarker assay measuring
S L C 7 A 5 ,H T F 9 C ,P 5 3 ,N D R G 1 ,a n dC E A C A M 5 .T h e s e
markers are independent of one another and do not
directly measure either proliferation or hormone recep-
tor status, and whilst there are caveats regarding the
extrapolation of immunohistochemistry to determine
the mutational status of individual genes, as a combined
index of five markers this panel has previously been
evaluated in three independent institutional cohorts, and
in a fourth combined analysis with the clinical trial spe-
cimens available from the NSABP 14 and B20 adjuvant
clinical trials [15,16]. In principle, therefore, Mammos-
trat® results could be interpreted in conjunction with
conventional histopathological information about the
proliferation and hormone receptor status of a tumor.
In the present article, we report the result of the largest
institutional validation study performed to date. We
explored the relationship of Mammostrat® risk stratifica-
tion in risk classes identified by standard pathologic and
clinical prognostic variables.
Materials and methods
The Edinburgh Breast Conservation Series represents a
fully documented, consecutive cohort of 1,812 patients
treated by breast-conservation surgery, axillary node
sampling or clearance, and whole-breast radiotherapy at
the Edinburgh Cancer Centre between 1981 and 1998.
Over this period patients were managed by a specialist
multidisciplinary team including surgeons, radiologists,
pathologists, and oncologists. Eligible patients were
those considered suitable for breast-conserving therapy
and were T1 or T2 (< 3 cm), N0 or N1, and M0 on
conventional TNM staging. Postoperative breast radio-
therapy was given over 4 to 5 weeks at a dose of 45 Gy
in 20 to 25 fractions. Data are available on adjuvant
treatment, tumor size, ER status, lymph node status and
outcome with a minimum follow-up of 9 years.
Following ethical approval (Lothian Local Research
Ethics 04), tissue blocks were retrieved from all cases,
and sufficient material was available from 1,686 cases
for assembly into tissue microarrays; all cases with avail-
able tissue were regarded by a single pathologist [17].
The ethical review board confirmed that informed con-
sent was not required for this study.
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motherapy only (n = 146) were excluded and 1,540
cases were stained using the Mammostrat® antibody
panel (Table 1). These cases included tumors treated
with adjuvant tamoxifen without chemotherapy (1,102
cases), with other hormonal therapy (92 cases), and with
both hormone therapy and chemotherapy (149 cases). In
addition, 197 cases received no adjuvant hormone ther-
apy or chemotherapy.
Biomarker analysis
Samples were stained, using triplicate 0.6 mm
2 tissue
microarray cores, and positivity for p53, HTF9C
(recently re-named TRIMT2A), CEACAM5, NDRG1,
and SLC7A5 was recorded as previously described
[15,16]. Briefly, scoring was on a semiquantitative scale,
where invasive breast cancer epithelium present in each
tissue core was scored as negative (0), weak (1), or
strong (2). CEACAM5 and NDRG1 were scored for
cytoplasmic or membrane staining, SLC7A5 for mem-
brane staining, HTF9C (TRIMT2A) for cytoplasmic
staining, and p53 for nuclear staining. With the excep-
tion of NDRG1, cases were considered positive if stain-
ing was present on > 10% of invasive tumor cells.
NDRG1 was scored as positive only when a core exhib-
ited homogeneous staining across the available sample.
A single investigator scored all replicates and then
inconsistencies between replicates were reviewed by two
investigators using an online image database to resolve
inconsistent replicates. The pair-wise concordance
between replicates prior to review was 95% for CEA-
CAM5, 88% for p53, 95% for SLC7A5, 89% for HTF9C
(TRIMT2A), and 93% for NDRG1. Consensus scores
across triplicate cores were generated considering the
case as positive if any of the three replicates was scored
positive. A Mammostrat® risk score was generated by
combining the five staining results as either positive or
negative according to the prospectively specified
Table 1 Patient characteristics within the study population by subgroup
Parameter All cases
(n = 1,540)
All ER-positive
(n = 1,189)
ER-positive tamoxifen only
a
(n = 831)
ER-positive, node-negative,
tamoxifen only
a (n = 657)
Age
< 50 years 660 (42.8%) 505 (42.5%) 284 (34.2%) 243 (37.0%)
> 50 years 879 (57.1%) 683 (57.4%) 547 (65.8%) 414 (63.0%)
Missing 1 (0.1%) 1 (0.1%)
Grade
1 411 (26.7%) 359 (30.2%) 269 (32.4%) 215 (32.7%)
2 710 (46.1%) 581 (48.9%) 416 (50.1%) 323 (49.2%)
3 381 (24.7%) 233 (19.6%) 135 (16.2%) 109 (16.6%)
Missing 38 (2.5%) 16 (1.3%) 11 (1.3%) 10 (1.5%)
Nodes
Negative 1164 (75.6%) 889 (74.8%) 657 (79.1%) 657 (100%)
1 to 3 321 (20.8%) 264 (22.2%) 154 (18.5%)
4 to 9 44 (2.9%) 29 (2.4%) 17 (2.0%)
10+ 9 (0.6%) 5 (0.4%) 3 (0.4%)
Missing 2 (0.1%) 2 (0.2%)
Size
< 20 mm 1150 (74.7%) 903 (75.9%) 648 (78.0%) 531 (80.8%)
> 20 mm 314 (20.4%) 224 (18.8%) 148 (17.8%) 99 (15.1%)
Missing 76 (4.9%) 62 (5.2%) 35 (4.2%) 27 (4.1%)
Estrogen receptor
< 2 278 (18.1%) 19 (1.6%) 15 (1.8%) 14 (2.1%)
Allred 3 to 5 347 (22.5%) 347 (29.2%) 213 (25.6%) 174 (26.5%)
Allred 6 to 8 823 (53.4%) 823 (69.2%) 603 (72.6%) 469 (71.4%)
Missing 92 (6.0%)
Progesterone receptor
< 2 242 (15.7%) 131 (11.0%) 90 (10.8%) 74 (11.3%)
Allred 3 to 5 334 (21.7%) 245 (20.6%) 180 (21.6%) 144 (21.9%)
Allred 6 to 8 866 (56.2%) 785 (66.0%) 542 (65.2%) 422 (64.2%)
Missing 98 (6.4%) 28 (2.4%) 19 (2.3%) 17 (2.6%)
ER, estrogen receptor.
aTamoxifen only, patients treated with adjuvant tamoxifen without adjuvant chemotherapy.
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transfer to the statistics team for cross-reference to the
clinical outcome data and analysis.
Statistical analysis
SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) was
used for all statistical analysis. Kaplan-Meier and log-
rank analysis were used to compare relapse-free survival
(RFS), distant recurrence-free survival (DRFS), and over-
all survival (OS). Hazard ratios and their confidence
intervals were calculated from log-rank statistics. All
reported P values are two-sided. In accordance with the
statistical analysis plan, patients were stratified into low,
medium and high risk, based on the integrated biomar-
ker expression profile (risk index).
Two prospectively defined primary analyses were per-
formed to address the ap r i o r ihypothesis that Mam-
mostrat® is a prognostic tool for ER-positive tamoxifen-
treated breast cancer. Firstly, DRFS was determined in
ER-positive, node-negative cases treated with tamoxifen
only and in ER-positive, tamoxifen-treated cases irre-
spective of nodal status. Further, exploratory, analyses
are reported in untreated cases, ER-negative cases, all
ER-positive cases, and all cases irrespective of hormonal
status and treatment. Univariate and multivariate ana-
lyses were performed for the Mammostrat® score in
each of these analyses with respect to RFS, DRFS and
OS (breast cancer specific).
Results
Of the 1,540 patients included in this study, 25% were
grade 3, 24% were node positive, 20% had large tumors
(> 2.0 cm) and 18% were ER-negative (Allred < 3) (see
Table 1 for clinicopathological parameters). For the pri-
mary, prospectively defined, analyses in this study, we
included only ER-positive tumors treated with tamoxi-
fen, excluding patients treated with adjuvant chemother-
apy (all patients received adjuvant radiotherapy), and
then stratified by nodal status. The 831 ER-positive
patients treated only with adjuvant tamoxifen were pre-
dominantly node-negative (79%, 657/831), presented
with tumor size < 2 cm (78%) and were ER rich (72%
Allred 6 or greater) (Table 1). For this population, 66%
were > 50 years of age and were regarded as postmeno-
pausal (Table 1).
Across all patients, Mammostrat® assigned 46.6% of
tumors to low-risk, 19.8% to moderate-risk and 18.1% to
high-risk strata (15.6% of cases had missing data for one
or more marker; complete data were available for 1,300
tumors) (Table 2). In ER-expressing, node-negative
patients treated with tamoxifen, 51.9% were low risk,
21.2% moderate risk, and 13.4% high risk (n =5 6 8 ,
13.5% missing data) (Table 2). Significantly more cases
were assigned to the Mammostrat® high-risk group in
the ER-negative population versus the ER-positive popu-
lation (45% vs. 16%, respectively; P < 0.0001). No
marked differences in Mammostrat® scores were
observed between the ER-positive groups (all patients,
tamoxifen-treated cases, and tamoxifen-treated, node-
negative cases) (Table 2).
ER-positive, node-negative, tamoxifen-treated cases
Following univariate analysis of the subgroup of ER-
positive, node-negative tumors treated with tamoxifen
(without chemotherapy, n = 568; Table 2), a significant
association was observed between the Mammostrat® risk
score and RFS (P = 0.016) and between the risk score
and DRFS (P = 0.003), with a trend observed for overall
survival (Table 3). At 10 years, the low-risk group had a
7.6% (standard error = 1.5%) distant recurrence rate, the
moderate-risk group 16.3% (standard error = 3.2%),
while the high-risk group exhibited a 20.9% distant
recurrence rate (Figure 1a, standard error = 4.4%, n =
88). The overall distant recurrence rate for the unstrati-
fied population was 11.1% (standard error = 1.2%). Simi-
lar statistically significant differences were observed for
RFS (Figure S1A in Additional file 1) and a trend was
observed for OS (data not shown). Tumors with both
high and moderate Mammostrat® risk scores showed
increased relative risk of local and distant relapse during
follow-up continuing over 15 years (Figure 1a).
In multivariate regression analysis, menopausal status,
multifocality, and HER2 were significant predictors of
RFS (Table 4), with a trend (P = 0.076) towards signifi-
cance for Mammostrat® scores. Only the Mammostrat®
score (P = 0.059) and HER2 status (P = 0.092) trended
towards significance for the prediction of DRFS and no
risk factors predicted for OS (Table 4). Exploratory uni-
variate analyses of the individual biomarkers revealed
that NRDG1 and p53 were individually significantly
associated with reduced DRFS, but only NDRG1 was
significantly associated with OS (Table 3).
ER-positive, tamoxifen-treated cases (node-negative and
node-positive combined)
Analysis of both node-positive and node-negative,
tamoxifen-treated, ER-positive cases with complete
Mammostrat® results (n = 731; Table 2) was also per-
formed. Univariate analysis of these patients showed a
significant association between the Mammostrat® risk
score and DRFS (P = 0.0001; Figure 1b), between the
score and RFS (P = 0.003; Figure S1B in Additional file
1), and between the score and OS (P = 0.001; Table 3,
and Figure S2B in Additional file 1). At 10 years, the
low-risk group had a 10.1% (standard error = 1.5%) dis-
tant recurrence rate, the moderate-risk group 20.8%
(standard error = 3.1%), while the high-risk group exhib-
ited a 25.6% distant recurrence rate (Figure 1b, standard
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rate for the unstratified population was 16.8% (standard
error = 1.0%). Exploratory univariate analyses of the
individual biomarkers revealed that HTF9C and NRDG1
were individually significantly associated with reduced
RFS, DRFS, and OS, whilst p53 was associated with RFS
and DRFS only (Table 3).
In multivariate analysis, the Mammostrat® risk score
remained an independent predictor of DRFS (P =
0.012) along with nodal status and HER2 status (all P
<0 . 0 5 ) .F o rO S ,t h eM a m m o s t r a t ® risk score was also
an independent predictor of outcome (P = 0.017) with
nodal status and HER2 (Table 4). For RFS, the nodal
status, tumor size, grade, menopausal status, multifo-
cality and HER2 status were significant risk predictors
with a trend towards significance for Mammostrat®
scores (P =0 . 0 6 4 ) .
All ER-positive cases
In univariate analysis of all 1,189 ER-positive cases (of
which data for low, medium or high Mammostrat Risk
scores were available in 1,055 cases; Table 2), there was
a significant association between Mammostrat® score
and DRFS (P < 0.00001; Figure 2a), between score and
RFS (P < 0.0001; Figure S1C in Additional file 1), and
between score and OS (P < 0.00001; Figure S2C in
Additional file 1) (Table 3 and Figure 2a). Exploratory
univariate analyses of the individual biomarkers revealed
that HTF9C, NRDG1, and p53 were individually signifi-
cantly associated with reduced RFS, DRFS, and OS
(Table 3).
In multivariate analyses within this patient group,
Mammostrat® scores were independent predictors
of RFS (P = 0.025 with nodal status, pathological size,
multifocality, menopausal status and HER2), of DRFS
Table 2 Biomarker results by subgroup
Biomarker All cases All ER-positive ER-positive tamoxifen only
a ER-positive, node-negative, tamoxifen only
a
SLC7A5
0 1231 (79.9%) 1035 (87.0%) 732 (88.1%) 578 (88.0%)
1 139 (9.0%) 77 (6.5%) 51 (6.1%) 38 (5.8%)
2 41 (2.7%) 24 (2.0%) 11 (1.3%) 9 (1.4%)
Missing
b 129 (8.4%) 53 (4.5%) 37 (4.5%) 32 (4.9%)
HTF9C
0 1234 (80.1%) 1015 (85.4%) 712 (85.7%) 559 (85.1%)
1 103 (6.7%) 69 (5.8%) 43 (5.2%) 35 (5.3%)
2 72 (4.7%) 46 (3.9%) 36 (4.3%) 25 (3.8%)
Missing 131 (8.5%) 59 (5.0%) 40 (4.8%) 38 (5.8%)
NDRG1
0 1085 (70.5%) 904 (76.0%) 624 (75.1%) 495 (75.3%)
1 175 (11.4%) 127 (10.7%) 96 (11.6%) 75 (11.4%)
2 148 (9.6%) 100 (8.4%) 66 (7.9%) 47 (7.2%)
Missing 132 (8.6%) 58 (4.9%) 45 (5.4%) 40 (6.1%)
CEACAM5
0 1251 (81.2%) 1005 (84.5%) 699 (84.1%) 550 (83.7%)
1 75 (4.9%) 67 (5.6%) 46 (5.5%) 39 (5.9%)
2 77 (5.0%) 61 (5.1%) 44 (5.1%) 29 (4.4%)
Missing 137 (8.9%) 56 (4.7%) 44 (5.3%) 39 (5.9%)
P53
0 1040 (67.5%) 884 (74.3%) 619 (74.5%) 479 (72.9%)
1 229 (14.9%) 166 (14.0%) 119 (14.3%) 101 (15.4%)
2 117 (7.6%) 67 (5.6%) 39 (4.7%) 30 (4.6%)
Missing 154 (10.0%) 72 (6.1%) 54 (6.5%) 47 (7.2%)
LMH
Low 717 (46.6%) 643 (54.1%) 444 (53.4%) 341 (51.9%)
Medium 305 (19.8%) 244 (20.5%) 175 (21.1%) 139 (21.2%)
High 278 (18.1%) 168 (14.1%) 112 (13.5%) 88 (13.4%)
Missing 240 (15.6%) 134 (11.3%) 100 (12.0%) 89 (13.5%)
Total 1300 1055 731 568
ER, estrogen receptor; LMH, low, medium, or high.
aTamoxifen only, patients treated with adjuvant tamoxifen without adjuvant chemotherapy.
bMissing data due
to loss of cores from tumor microarrays or no tumor in the tumor microarray core.
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cality and HER2), and of OS (P = 0.0023, with patholo-
gical size, grade and nodal status also significant).
All eligible cases (1,300 cases)
Univariate analysis of all cases with complete Mammos-
trat® data irrespective of ER status, nodal status or treat-
ment showed a highly significant association between
Mammostrat® score and DRFS (Figure 2b), between
score and RFS (Figure S1D in Additional file 1), and
between score and OS (all P < 0.00001; Figure S2D in
Additional file 1). Exploratory univariate analyses of the
individual biomarkers revealed that SLC7A5, HTF9C,
NRDG1, and p53 were individually significantly asso-
ciated with reduced RFS, DRFS, and OS, whilst CEA-
CAM5 was significantly associated only with DRFS
(Table 3).
In multivariate analyses, Mammostrat® scores were
independent predictors of RFS (P = 0.0007, with nodal
status, pathological size, multifocality, and HER2 status
all P < 0.001), DRFS (P = 0.00007, with nodal status,
pathological size, and HER2 status all P <0 . 0 2 ) ,a n dO S
(P = 0.005 with ER, pathological size and nodal status
also significant).
Table 3 Results of univariate analysis for individual biomarkers and Mammostrat® risk score
Recurrence-free survival Distant recurrence-free survival Overall survival
ER-positive, tamoxifen treated, node-negative
SLC7A5 NS NS NS
HTF9C NS NS NS
NRDG1 NS 1.79 (1.11 to 2.88), P = 0.015 NS
CEACAM5 NS NS NS
P53 NS 1.60 (1.01 to 2.54), P = 0.045 NS
LMH P = 0.016 P = 0.003 NS
LvH 1.78 (1.08 to 2.95), P = 0.025 2.30 (1.31 to 4.05), P = 0.004
LvM 1.73 (1.12 to 2.68), P = 0.014 2.01 (1.21 to 3.35), P = 0.007
ER-positive, tamoxifen treated
SLC7A5 NS NS NS
HTF9C 1.61 (1.04 to 2.50), P = 0.032 1.87 (1.17 to 2.98), P = 0.008 NS
NRDG1 1.45 (1.02 to 2.05), P = 0.037 1.83 (1.26 to 2.67), P = 0.001 1.64 (1.21 to 2.21), P < 0.0005
CEACAM5 NS NS NS
P53 1.43 (1.02 to 2.01), P = 0.036 1.64 (1.13 to 2.39), P = 0.008 NS
LMH P = 0.003 P = 0.0001 P = 0.006
LvH 1.80 (1.20 to 2.70), P = 0.005 2.23 (1.43 to 3.49), P = 0.0005 1.99 (1.17 to 3.41), P = 0.012
LvM 1.65 (1.15 to 2.35), P = 0.006 1.99 (1.33 to 2.97), P = 0.0008 1.88 (1.20 to 2.96), P = 0.006
All ER-positive cases
SLC7A5 NS NS NS
HTF9C NS 1.51 (1.01 to 2.27), P = 0.048 NS
NRDG1 1.51 (1.13 to 2.02), P = 0.005 1.84 (1.34 to 2.52), P = 0.0001 1.82 (1.42 to 2.34), P < 0.0005
CEACAM5 NS NS NS
P53 1.39 (1.05 to 1.85), P = 0.02 1.56 (1.14 to 2.13), P = 0.005 NS
LMH P < 0.0001 P < 0.00001 P < 0.00001
LvH 1.80 (1.26 to 2.57) 2.19 (1.49 to 3.24), P = 0.00008 2.16 (1.39 to 3.56), P = 0.0006
LvM 1.78 (1.31 to 2.40), P = 0.0002 2.10 (1.49 to 2.95), P = 0.00002 2.26 (1.55 to 3.30), P = 0.00002
All cases
SLC7A5 1.45 (1.08 to 1.95), P = 0.012 1.63 (1.19 to 2.22), P = 0.002 1.39 (1.06 to 1.80), P = 0.015
HTF9C 1.45 (1.07 to 1.95), P = 0.015 1.57 (1.14 to 2.16), P = 0.005 1.37 (1.05 to 1.79), P = 0.021
NRDG1 1.58 (1.25 to 2.01), P < 0.0005 1.86 (1.43 to 2.40), P < 0.0005 1.76 (1.43 to 2.17), P < 0.0005
CEACAM5 NS 1.44 (1.03 to 2.02), P = 0.034 NS
P53 1.57 (1.25 to 1.98), P < 0.0005 1.80 (1.40 to 2.31), P = 0.010 1.32 (1.07 to 1.63), P = 0.010
LMH P < 0.00001 P < 0.00001 P < 0.00001
LvH 2.02 (1.54 to 2.64) 2.53 (1.89 to 3.40) 2.62 (1.89 to 3.63)
LvM 1.74 (1.33 to 2.28) 2.02 (1.49 to 2.73) 2.24 (1.61 to 3.11)
All individual markers analyzed as dichotomous variables. ER, estrogen receptor; LMH, P value for significance of Mammostrat® score; LvM, hazard ratio (95%
confidence interval) for low-risk versus medium-risk cases classified by Mammostrat®; LvH, hazard ratio (95% confidence interval) for low-risk versus high-risk
cases classified by Mammostrat®; NS, nonsignificant.
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The Breast Conservation Series cohort analyzed
included small numbers of ER-negative cases (265 with
complete Mammostrat® data) and untreated cases (both
ER-positive and ER-negative, 167 with complete Mam-
mostrat® data). In univariate analysis, ER-negative cases
showed a significant relationship with DRFS (P =0 . 0 0 9
Figure 2c) while untreated cases also showed a signifi-
cant outcome (P = 0.026 Figure 2d). Similar results were
observed for RFS and OS (see Figures S1E, S1F, S2E,
and S2F in Additional file 1). Therefore, whilst ER-nega-
t i v ec a s e sw e r em o r ef r e q u e n t l yd e s i g n a t e dh i g hr i s k
than ER-positive cases (see above), there was no evi-
dence in these exploratory analyses that Mammostrat®
performed differently in ER-negative cases and untreated
breast cancers when compared with ER-positive cases.
Discussion
In a retrospective analysis of ER-positive early breast
cancer, treated in a single institution with breast-conser-
ving therapy, a prognostic score derived from a simple
five-antibody test (Mammostrat®) was significantly asso-
ciated with RFS, DRFS and OS, and was independent of
standard clinical and pathological risk factors. In a
population-based analysis, including all breast cancers
irrespective of ER status, the relationships were pre-
served (Figure 2b, Figures S1D and S2D in Additional
file 1, and Table 4). Subgroup analyses of ER-positive
cancers, node-positive versus node-negative cancers,
tamoxifen-treated cancers, ER-negative cancers and
untreated cancers showed no group in which the Mam-
mostrat® score failed to select patients at high risk and
low risk of recurrence (Figures 1 and 2).
In the prospectively defined target population - ER-
positive, node-negative patients treated with tamoxifen
therapy only (n = 568) - low-risk patients had a 10-year
distant recurrence rate of 7.6% compared with 20.9% for
high-risk patients. Multivariate analysis of this popula-
tion and of the slightly larger ER-positive, tamoxifen-
treated group (with both node-positive and node-nega-
tive cancers, n = 731) did not, in this low-risk popula-
tion treated with breast-conserving surgery and
radiotherapy, identify Mammostrat® as an independent
risk factor. However, in these subpopulations only nodal
status was consistently linked to outcome (RFS, DRFS,
and OS). It would appear that the small number of
events in this subgroup restricts the power to robustly
identify key prognostic variables. This interpretation is
further supported by the consistent impact of Mammos-
trat® across all populations in univariate analyses (Table
3), exemplified by the almost identical hazard ratios
observed in all subgroups analyzed.
This is the third independent institutional study sup-
porting the association of Mammostrat® with clinical
outcome independent of conventional risk factors, and
is consistent with resultsf r o mt h es t u d yo fM a m m o s -
trat® in the NSABP B14 and B20 clinical trial samples
[15,16]. In the current study, Mammostrat® appears to
function as a prognostic tool in node-positive and node-
negative disease and in both ER-negative and ER-posi-
tive populations, and acts consistently independently of
menopausal status. In the published NSABP B20 study,
patients deemed high risk had a robust response to
Figure 1 Co-primary endpoints. Kaplan-Meier distant recurrence-
free survival (DRFS) survival curves for breast-conserving surgery
cases. Solid lines, Mammostrat® score low risk; dotted lines,
Mammostrat® score medium risk; grey lines, Mammostrat® score
high risk. (a) Estrogen receptor (ER)-positive, node-negative breast
cancers treated with adjuvant tamoxifen only. (b) ER-positive,
tamoxifen-treated breast cancers (any nodal status).
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test is identifying patients that would benefit from a
more aggressive treatment regimen [14].
As with other multiparameter prognostic tools, Mam-
mostrat® appears to identify biological drivers of disease
relapse that complement conventional pathological mar-
kers (grade, tumor size, nodal status) and other biologi-
cal markers (for example, HER2). To date, we have
analyzed the results of the Mammostrat® panel indepen-
dently of these biological and clinical risk parameters.
Unlike the OncotypeDx and Mammaprint assays, there-
fore, Mammostrat® does not incorporate hormone
receptor status, HER2 status, or measures of
proliferation into its risk-stratification algorithm, allow-
ing it to be performed independently of current mea-
surements of growth and hormone receptor status and
Ki67 staining or mitotic count indexes. Incorporation of
Mammostrat® into nomograms that weight clinical stra-
tifiers and these conventional biomarkers, such as Adju-
vant Online! and the Nottingham Prognostic Index, has
the potential to give a full accounting of the clinically
relevant biologic diversity of breast cancer in consider-
ing therapy options. We are currently exploring such an
analysis within a sufficiently powered patient cohort.
Breast cancer prognostic markers remain central for
treatment decisions and, particularly for ER-positive
Table 4 Results of multivariate regression analysis including Mammostrat® risk score
ER-positive, node-negative, tamoxifen only
a ER-positive, tamoxifen only
a All ER-positive cases All Eligible cases
Relapse-free survival
Nodal status * 5.4 × 10
-8 0.0001 2.8 × 10
-9
Grade NS 0.046 NS NS
Size NS 0.010 7.0 × 10
-5 0.0007
Multifocality 0.037 0.001 0.0004 0.0004
Menopausal status 0.031 0.013 0.048 NS
Age NS NS NS NS
HER2 0.012 0.0005 0.003 0.001
PgR NS NS 0.079 NS
ER * * * NS
Mammostrat® 0.076 0.064 0.025 0.0007
Distant recurrence-free survival
Nodal status * 3.7 × 10
-7 5.1 × 10
-5 4.6 × 10
-9
Grade NS 0.067 NS NS
Size 0.091 0.0004 0.002
Multifocality NS NS 0.030 0.082
Menopausal status NS NS NS NS
Age NS NS NS NS
HER2 0.092 0.01 0.021 0.024
PgR NS NS NS NS
ER * * * NS
Mammostrat® 0.059 0.012 0.005 6.6x10-5
Overall survival
Nodal status * 2.5 × 10
-6 6.9 × 10
-5 9.1 × 10
-9
Grade NS 0.074 0.036 0.088
Size 0.018 0.00021 0.011
Multifocality NS NS 0.061 NS
Menopausal status NS NS NS NS
Age NS 0.080 0.037 0.017
HER2 NS NS NS NS
PgR NS 0.059 0.085 NS
ER * * * 0.001
Mammostrat® NS NS 0.0023 0.005
Data represent P value for significance of individual factors in multivariate analyses. ER, estrogen receptor; NS, not significant. Nodal status, node-positive versus
node-negative; grade, grade 1, grade 2 or grade 3; size, < 2 cm vs. ≥ 2 cm; multifocality, presence or absence of multifocal disease; menopausal status,
premenopausal versus postmenopausal; age, < 55 years versus ≥ 55 years; HER2, HER2-positive versus HER2-negative; PgR (progesterone receptor) and ER,
hormone receptor-positive versus hormone receptor-negative; Mammostrat®, risk category low, medium or high.
aTamoxifen only, patients treated with adjuvant
tamoxifen without adjuvant chemotherapy. * = not relevant as no stratification, e.g. nodal status in node negative patients.
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motherapy in low-risk breast cancers. There is wide
consensus that the currently available prognostic mar-
kers do not adequately stratify breast cancer - this is
backed up by data from the Oxford overviews [1], which
show that a significant minority of patients do not
require chemotherapy and that the role of chemotherapy
in low-risk, ER-positive breast cancer remains uncertain.
Two international trials (TailorX and Mindact) are seek-
ing to explore the value of using additional biological
markers to further risk stratify breast cancers (Oncoty-
peDx and Mammaprint, respectively) and to identify
patient populations for whom aggressive treatment with
chemotherapy is of little or no benefit. We are unaware
of any study currently seeking to evaluate different bio-
marker approaches in a direct comparison.
Current trials rely on complex molecular profiles
using either expression arrays or multiplex quantitative
PCR techniques that must be performed in a single cen-
tral laboratory. Neither technique has been shown to be
widely applicable in routine diagnostic pathology.
Immunohistochemistry, however, has wide application
and, with appropriate external quality assurance (for
example, NEQAS UK), is highly consistent across multi-
ple laboratories. Whilst, to date, the Mammostrat® IHC
profile has only been performed in a central laboratory,
there is evidence that this technology will prove applic-
able in routine diagnostic pathology. The adaptation of
these methods to merge with current developments in
quantitative IHC (for example, AQUA) and image analy-
sis could further standardize delivery of multiplex panels
that are far more cost-effective than complex molecular
profiling. Rapid progress in image analysis and quantita-
tive IHC [18,19] for other prognostic markers (ER, pro-
gesterone receptor, HER2, and so forth) suggests that
this is an area of significant potential. One of the key
requirements for any diagnostic pathology assay is that
the assay is portable or reproducible across multiple
centers. A key future step in the validation of the Mam-
mostrat® assay, therefore, is a demonstration that identi-
cal results can be derived on the same samples in
different laboratories. Such ring studies have proven of
significant value in validating other novel diagnostics,
particularly in the field of HER2 testing [20,21].
Figure 2 Exploratory analysis. Kaplan-Meier distant recurrence-free survival (DRFS) survival cures for breast-conserving surgery cases. Solid lines,
Mammostrat® score low risk; dotted lines, Mammostrat® score medium risk; grey lines, Mammostrat® score high risk. (a) All estrogen receptor
(ER)-positive breast cancers. (b) All breast cancers regardless of treatment and hormonal status. (c) Untreated breast cancers. (d) ER-negative
breast cancers.
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The present study provides further data on the use of
Mammostrat® in predicting the prognosis of early-stage,
ER-positive, and ER-negative breast tumors. Although
numbers of ER-negative and untreated cases were small,
the evidence is consistent with Mammostrat® acting as a
prognostic tool in all early breast cancers. When viewed
in context with other published studies, the data on
stratification of ER-positive breast cancers across five
independent cohorts is clearly most robust. The Mam-
mostrat® markers are biologically independent of one
another and measure aspects of physiology distinct from
proliferation, HER2 status, and hormone receptor status
already assessed by IHC assays that are standard of care.
Collectively these data add support to a potential role
for Mammostrat® in management of early-stage breast
cancer.
Additional material
Additional file 1: Recurrence-free survival and overall survival for
breast-conserving surgery breast cancers. Figure S1 shows Kaplan-
Meier recurrence-free survival curves for breast-conserving surgery breast
cancers. Solid lines, Mammostrat® score low risk; dotted lines,
Mammostrat® score medium risk; grey lines, Mammostrat® score high risk.
(S1A) Estrogen receptor (ER)-positive, node-negative breast cancers
treated with adjuvant tamoxifen only. (S1B) ER-positive, tamoxifen-treated
breast cancers (any nodal status). (S1C) All ER-positive breast cancers.
(S1D) All breast cancers regardless of treatment and hormonal status.
(S1E) Untreated breast cancers. (S1F) ER-negative breast cancers. Figure
S2 shows Kaplan-Meier overall survival curves for breast-conserving
surgery breast cancers. Solid lines, Mammostrat® score low risk; dotted
lines, Mammostrat® score medium risk; grey lines, Mammostrat® score
high risk. (S2A) Estrogen receptor (ER)-positive, node-negative breast
cancers treated with adjuvant tamoxifen only. (S2B) ER-positive,
tamoxifen-treated breast cancers (any nodal status). (S2C) All ER-positive
breast cancers. (S2D) All breast cancers regardless of treatment and
hormonal status. (S2E) Untreated breast cancers. (S2F) ER-negative breast
cancers.
Abbreviations
DRFS: distant recurrence-free survival; ER: estrogen receptor; IHC:
immunohistochemistry; OS: overall (breast cancer specific) survival; RFS:
relapse-free survival.
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